Regulatory Approval Timeline of Active Immunotherapies The clinical development of active immunotherapies has exploded in the last ten years. Checkpoint inhibitors, in particular PD-1 and PD-L1, have been integrated into standard-of-care across many cancer types. The CRI Anna-Maria Kellen Clinical Accelerator team has tracked the FDA approval timeline of active immunotherapies, noting both their increase in frequency and gradually expanding range of cancer types and stages. Anti-PD-1/L1 Antibody Approvals by U.S. FDA Timeline of Anti-PD-1/L1 Antibody Approvals by the FDA Other IO Agent Approvals by U.S. FDA Timeline of non-PD-1/PD-L1 Immuno-Oncology Agent Approvals by the FDA Anti-PD-1/L1 Antibody Approvals by EU, Japan, and China Timeline of Anti-PD-1/L1 Antibody Approvals by the European Medicines Agency (EMA) for the European Union (EU), National Medical Products Administration (NMPA) for China, and Pharmaceuticals and Medical Devices Agency (PMDA) for Japan. More Resources for FDA Approval Timeline of Active Immunotherapies Read about the early results of the PRINCE clinical trial (NCT03214250) on the CRI Immune to Cancer Blog. READ IO LANDSCAPE PUBLICATIONS DOWNLOAD A PDF OF THE LATEST CRI LANDSCAPE FIGURES Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute. Subscribe to our email newsletter to receive the latest updates on our landscape analyses. Do you want more information on the Clinical Accelerator? Contact us. IO Landscapes Immuno-Oncology Landscape Cancer Cell Therapy Landscape PD-1/PD-L1 Immune Checkpoint Inhibitors Landscape Pancreatic Cancer IO Landscape Regulatory Approval Timeline of Active Immunotherapies COVID-19 and Clinical Trials Stay up to date Get the latest cancer immunotherapy updates. Subscribe to the CRI email newsletter. Name: Field Is Required First Field Is Required Last Email: Field Is Required Email: Spam Control Text: Please leave this field empty
